Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

OPENAI DEFINES FIVE 'LEVELS' FOR AI TO REACH HUMAN INTELLIGENCE

OpenAI recently shared a five-level system for tracking its artificial general intelligence progress. The levels go from what is currently available to AI that can perform the same amount of work as an organization. They may change based on feedback from employees, investors, and the company's board. OpenAI executives believe the company's AI is currently on the first level, but it is getting close to level two, where AI can perform basic problem-solving.

ZERO TO BILLIONS: THE STARTUP ON THE VERGE OF THE BIGGEST TECH EXIT IN YEARS

Cloud cybersecurity company Wiz was founded four years ago by four former Israeli military officers. It grew quickly to become the dominant company in cloud cybersecurity and is headed toward the largest exit for any tech startup since Rivian's $77 billion initial public offering in November 2021. Google is looking to acquire the company for a $23 billion sale price. The deal will likely draw scrutiny from antitrust regulators in the US and EU.

IMMUNOTHERAPY IS CHANGING CANCER TREATMENT FOREVER

The human immune system is very good at attacking anything it registers as a disease - if it could be turned against cancer, it could eliminate tumors more thoroughly than surgery and more durably than chemotherapy. Scientists have managed to modify T cells to react to cancer as if it were a virus and destroy it. The therapy has been used to remove glioblastomas, a common type of brain cancer with a median time of diagnosis to death of just over a year.

WHERE'S THE SYNTHETIC BLOOD?

The creation of synthetic blood is one of the holy grails of biomedical research. There are two main approaches to making synthetic blood products: the biologist's approach and the chemist's approach. The biologist's approach involves coaxing stem cells into becoming blood cells, while the chemist's approach synthesizes molecules and particles that mimic the functions of blood cells. Both approaches need to overcome economic and manufacturing challenges before they can scale for use in patients.

TLDR IndexPage 1